[ad_1]
Arcturus Therapeutics Holdings Inc. ((the “Company”, “Arcturus”, Nasdaq:ARCT), a leading clinical-stage messenger RNA pharmaceuticals company focused on the development of infectious disease vaccines and significant opportunities in rare diseases of the liver and respiratory tract, today announced that the Compensation Committee of the Company’s Board of Directors and the Company’s Board of Directors approved an incentive grant to a new hire Purchase stock options for a total of 5,800 shares of Arcturus common stock. Equity awards are granted under the NASDAQ Rule 5635(c)(4) incentive grant exception as part of each individual’s employment compensation and are awarded as incentive material for him or her to accept employment with the company.
The strike price of the options is equal to $27.21 per share, the closing price of the company’s common stock as reported by Nasdaq on January 18, 2022. Option for a 10-year term and a 4-year grant term for 25% of the option number of stock option-related shares vested on the first anniversary of the applicable vesting start date (based on the quarter in which the applicable employee began employment), the remainder of the shares thereafter 36 Monthly vesting within the month. Equity awards depend on each person’s continued service…
The full story is available on Benzinga.com
[ad_2]
Source link
